Trials / Completed
CompletedNCT04717466
Brain Changes in Psoriasis After Secukinumab Treatment
Brain Morphological Changes Accompanied by Effective Biologic Treatments for Psoriasis and Their Associations With the Improvement of Well-being, Itch, and Pain
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Secukinumab | 300mg subcutaneous injection |
Timeline
- Start date
- 2021-06-29
- Primary completion
- 2024-05-16
- Completion
- 2025-03-04
- First posted
- 2021-01-22
- Last updated
- 2025-06-05
- Results posted
- 2025-06-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04717466. Inclusion in this directory is not an endorsement.